Current Report Filing (8-k)
April 03 2020 - 7:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 3, 2020
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36714
|
|
46-2956775
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
201 Mission Street, Suite 2375
San Francisco, California
|
|
94105
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. x
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.0001 Per Share
|
JAGX
|
The NASDAQ Capital Market
|
Item 7.01
|
Regulation FD Disclosure.
|
On April 3, 2020, Jaguar Health, Inc. (the “Company”) issued a press release announcing that it will conduct a
conference call on Monday, April 6, 2020 at 8:30 a.m. ET / 5:30 a.m. PT to provide updates regarding fourth quarter 2019 financials
and business updates. A copy of the press release is furnished as Exhibit 99.1.
The information in Item 7.01 and the press release furnished
as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, or incorporated
by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in any such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
JAGUAR HEALTH, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Lisa A. Conte
|
|
|
Name:
|
Lisa A. Conte
|
|
|
Title:
|
Chief Executive Officer & President
|
|
|
|
|
Date: April 3, 2020
|
|
|
|
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jul 2023 to Jul 2024